Malaria Treatment Market Forecast 2025-2035: Growth, Key Players, and Emerging Therapies Driving Industry Expansion

The Global Malaria Treatment Market is poised for strong growth, with sales projected to reach USD 3,113.8 million by 2035, up from USD 1,894.5 million in 2025. This represents a steady CAGR of 5.1% from 2025 to 2035, driven by increasing disease prevalence, global health initiatives, and rapid advancements in antimalarial drug technologies.

Malaria continues to be one of the most significant public health challenges worldwide, particularly in tropical and subtropical regions. According to the World Health Organization (WHO), more than 247 million malaria cases were reported in 2022, underscoring an urgent demand for effective prevention, diagnosis, and treatment solutions. Sub-Saharan Africa remains the most severely affected region, accounting for the majority of global cases and deaths.

This Report Now at Just $5000 | Limited-Time Discount Offer! https://www.futuremarketinsights.com/reports/sample/rep-gb-15905

Global Malaria Treatment Industry Overview

Attributes

Key Insights

Historical Size (2024)

USD 1,830.6 million

Estimated Size (2025)

USD 1,894.5 million

Projected Size (2035)

USD 3,113.8 million

CAGR (2025–2035)

5.1%

The market growth is being reinforced by large-scale global health programs and partnerships such as the WHO Global Malaria Program and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, which ensure access to affordable, high-quality antimalarial drugs in low- and middle-income countries. Philanthropic organizations like the Bill & Melinda Gates Foundation continue to play a pivotal role by funding innovative drug and vaccine development to combat resistant malaria strains.

Semi-Annual Growth Snapshot

The malaria treatment market is expected to maintain a positive trajectory:

• H1 2025–2035 CAGR: 5.1%
• H2 2025–2035 CAGR: 4.7%

While growth rates may slightly moderate over time, steady innovation and increased global health spending will sustain long-term expansion.

Key Market Drivers

1. Rising Global Malaria Prevalence

The continuous increase in malaria cases—especially in Sub-Saharan Africa and Southeast Asia—remains the leading growth driver. Vulnerable populations such as children under five and pregnant women represent a substantial patient base requiring consistent treatment access.

2. Technological Advancements in Drug Development

Major pharmaceutical companies and research institutions are developing next-generation antimalarial therapies, including single-dose cures and pediatric-friendly formulations. Novel drugs like tafenoquine and triple ACTs are designed to overcome growing resistance to artemisinin-based combination therapies (ACTs), currently the gold standard in malaria treatment.

3. Increasing Public-Private Partnerships

Collaborations between governments, NGOs, and pharmaceutical manufacturers have become critical in expanding the reach of malaria treatments. Initiatives by organizations such as Medicines for Malaria Venture (MMV) and PATH demonstrate how public-private efforts enhance accessibility and affordability, particularly in rural and underserved regions.

4. Expanding Global Funding and Support

Massive investments from international donors have fueled advancements in diagnostics, drug development, and vaccine research. Countries supported by the Global Fund and WHO have reported higher treatment access rates and improved health infrastructure.

Challenges Restricting Growth

Despite the market’s positive outlook, drug resistance—especially to artemisinin—poses a serious threat. Misuse of antimalarial drugs, counterfeit medications, and incomplete treatment courses contribute to the rise of resistant Plasmodium strains. This challenge demands continued R&D investment and robust regulatory oversight to ensure quality control and drug efficacy.

Comparative Market Analysis (2020–2035)

Between 2020 and 2024, the market recorded a CAGR of 4.1%, largely supported by ACT adoption and better diagnostic access. Moving forward, the introduction of novel antimalarial compounds, improved surveillance, and regional manufacturing capabilities will further boost market resilience.

Market Structure and Key Players

The global malaria treatment market is moderately consolidated, with a mix of established leaders and emerging innovators:

• Tier 1 Players (58.3% Market Share):
• Novartis AG, Sanofi, Ajanta Pharma, Pfizer Inc. – Known for extensive product portfolios, advanced R&D, and wide geographic presence.
• Tier 2 Players (35.7% Market Share):
• F. Hoffmann-La Roche Ltd, Merck & Co., Inc., GlaxoSmithKline (GSK) – Focused on cost-efficient production and competitive pricing in niche markets.
• Tier 3 Players:
• Cipla Limited, Ipca Laboratories, and regional manufacturers – Concentrating on affordable, locally produced antimalarial drugs catering to specific national markets.

Regional Outlook

Middle East & Africa

• Nigeria: Expected CAGR of 7.0%, the highest globally.
• Nigeria accounts for nearly 27% of global malaria cases, driven by year-round mosquito breeding and high infection rates. Government programs like the National Malaria Elimination Programme (NMEP), supported by the Global Fund, continue to improve access to effective ACTs.
• Uganda: Projected CAGR of 6.0%.
• Strong government and NGO collaboration under the National Malaria Control Program enhances drug distribution and community awareness.

Asia

• India: Projected CAGR of 4.8%.
• Substantial government funding under the National Framework for Malaria Elimination (NFME) and partnerships with the Bill & Melinda Gates Foundation have advanced drug development and vaccine trials.

Market Segmentation Highlights

By Drug Type

• Artemisinin-Based Combination Therapies (ACTs):
• Value Share (2025): 45.6%
• Dominates the market due to superior efficacy against Plasmodium falciparum.
• Supported by WHO and global health initiatives ensuring widespread availability.

By Route of Administration

• Oral Segment:
• Value Share (2025): 70.7%
• Preferred for convenience, affordability, and ease of distribution in low-resource settings.

By Distribution Channel

• Public Sales: Supported by government and NGO programs.
• Private Sales: Growing through retail pharmacies and e-commerce expansion.

Recent Industry Developments

• October 2024: AMIVAS Ireland Ltd launched Artesunate AMIVAS, expanding access to intravenous malaria treatments.
• July 2024: GSK plc and Medicines for Malaria Venture introduced tafenoquine in Thailand and Brazil—the first single-dose cure for P. vivax malaria relapse.
• April 2024: Novartis and MMV reported successful trial results for Coartem® (artemether-lumefantrine) in infants under 5 kg.

Key Segments of the Malaria Treatment Market

• By Drug Type:
• Artemisinin-Based Combination Therapies (ACTs)
• Quinine & Derivatives
• Antifolates
• Atovaquone-Based Drugs
• Others
• By Route of Administration:
• Oral
• Injectable
• By Type:
• Branded
• Generic
• By Distribution Channel:
• Public
• Private
• By Region:
• Latin America
• Asia
• Middle East & Africa

Checkout Now to Access Industry Insights: https://www.futuremarketinsights.com/checkout/15905

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.